
Precision BioSciences Reports Initial Safety and Antiviral Activity Data for PBGENE-HBV in the ELIMINATE-B Trial
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company leveraging its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs, has announced…













